ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
Millie Das(VA Palo Alto Health Care System), Richard H. Bruce(Palo Alto Research Center), Jorge J. Nieva(University of Southern California), Janey C. Ly(SRI International), Jonathan W. Riess(University of California Davis Medical Center), Paul Frankel(City of Hope), Robyn Bennis(Palo Alto Research Center), Lisa Zhou(Stanford University), Erich Schwartz(Stanford Medicine), Heather A. Wakelee(Palo Alto Institute), Huangpin B. Hsieh(Palo Alto Research Center), Xiaohe Liu
Cited by 59
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805